Dendritic Nanotechnologies gets US contract for ovarian cancer diagnostic and drug delivery:
This article was originally published in Clinica
Dendritic Nanotechnologies (DNT) has teamed with the US National Cancer Institute (NCI) to develop diagnostic and therapeutic delivery systems for ovarian cancer using its dendrimer nanostructures know-how. The partners have entered into an $850,000 small business innovation research contract, whereby DNT's Priostar dendrimer delivery system will be combined with a magnetic resonance imaging agent to create an improved product for detecting and monitoring cancerous tissue. A second product will combine the Priostar dendrimer with approved cancer-fighting drugs to improve and deliver therapy for ovarian epithelial cancer. Mount Pleasant, Michigan-based DNT expects the project to result in the filing of investigational new drug (IND) applications for the diagnostic imaging technology and for the therapeutic technology. Dendrimers are a type of precisely-defined, branched nanostructure.
You may also be interested in...
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.